Pharmaceutical company Novo Nordisk has disclosed that a cyberattack led to the theft of data related to clinical trial participants. The company emphasized that the affected data was pseudonymized, meaning it was not directly associated with names or other identifiable information.
Details of the Stolen Data
The compromised data includes various types of information such as patient ID, details on trial participation, gender, year of birth, biomarkers, health and immunogenicity data, as well as lifestyle factors like smoking status, alcohol consumption, and body mass index (BMI). Novo Nordisk stated, “This information is not directly linked to any patients by name or other direct identifiers.” This suggests that identifying participants would require access to additional underlying information that was not exposed during the breach.
Impact on Internal Systems
The company reported that the cyberattack affected a limited number of internal IT systems, prompting some to be taken offline as a precautionary measure. Although Novo Nordisk believes there is no immediate risk from the breach, it has advised patients to remain vigilant for any potential issues related to the stolen data.
Risks to Healthcare Partners
A separate communication to healthcare partners indicated that additional personal information may have been compromised, which could lead to targeted phishing attempts. The exposed data for healthcare partners includes names, registration numbers, email addresses, phone numbers, WhatsApp details, and office locations. Novo Nordisk warned that this could result in fraudulent communications or impersonation attempts, urging partners to be cautious of unexpected messages or calls.
Ongoing Investigation and Business Operations
While external experts have been engaged to investigate the breach, Novo Nordisk has not confirmed the scale of the incident. The company reassured that its core business operations remain unaffected and are continuing as normal. The announcement of the cyberattack coincided with a significant milestone for Novo Nordisk, as its Wegovy weight-loss drug received regulatory approval in the UK.
This article was produced by NeonPulse.today using human and AI-assisted editorial processes, based on publicly available information. Content may be edited for clarity and style.
